{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:55:58Z","timestamp":1781862958087,"version":"3.54.5"},"reference-count":75,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The prognosis of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has improved with the addition of tyrosine kinase inhibitors (TKIs) to conventional chemotherapy. However, there are limited therapeutic options for patients resistant or intolerant to current TKIs. Methods: A comprehensive search was made on PubMed.ncbi.nlm.nih.gov for published studies and ClinicalTrials.gov for registered trials, regarding the first results of and promising strategies with olverembatinib, a novel third-generation TKI, for the treatment of Ph+ ALL. Results: First trials involving olverembatinib showed significant anti-leukemic clinical activity both in newly diagnosed and relapsed\/refractory patients with Ph+ ALL, especially those harboring the T315I mutation. Furthermore, olverembatinib demonstrated a favorable tolerability compared with the other TKIs. Conclusions: This augurs a new era in the standard of care for many patients with unmet clinical needs. However, further studies are warranted to assess olverembatinib\u2019s real value and its cost-effectiveness.<\/jats:p>","DOI":"10.3390\/cancers18121990","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:18:43Z","timestamp":1781860723000},"page":"1990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olverembatinib: A New Treatment for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2404","authenticated-orcid":false,"given":"Xavier","family":"Thomas","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Department of Clinical Hematology, Centre Hospitalier Universitaire, F-69003 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: First approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"key":"ref_3","first-page":"119","article-title":"Philadelphia chromosome positive adult acute lymphoblastic leukemia: Characteristics, prognostic factors and treatment outcome","volume":"40","author":"Thomas","year":"1998","journal-title":"Hematol. Cell Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.2023023502","article-title":"Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia","volume":"143","author":"Chalandon","year":"2024","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Vitale","year":"2011","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Bassan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1002\/hem3.67","article-title":"Ponafil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results","volume":"8","author":"Ribera","year":"2024","journal-title":"Hemasphere"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","article-title":"Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"18","author":"Jabbour","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/10428194.2024.2432582","article-title":"Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"66","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_22","first-page":"100294","article-title":"Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"17","author":"Ueda","year":"2022","journal-title":"Leuk. Res. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: A US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","article-title":"A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia: Final results of the GIMEMA LAL1509 protocol","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87002","DOI":"10.18632\/oncotarget.10881","article-title":"GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and Pl3K\/AKT pathways","volume":"8","author":"Ye","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.tranon.2020.100766","article-title":"GZD824 as a FLT3, FGFR1 and PDGFR\u03b1 inhibitor against leukemia in vitro and in vivo","volume":"13","author":"Wang","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023\u2013common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1111\/cts.70021","article-title":"Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers","volume":"17","author":"Wang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/1538-7445.AM2021-1463","article-title":"ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","article-title":"Olverembatinib treatment in pediatric patients with relapsed Philadelphia-chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","first-page":"2343","article-title":"The BCR gene and Philadelphia chromosome-positive leukemogenesis","volume":"61","author":"Laurent","year":"2001","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1007\/s00432-022-04562-5","article-title":"Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors","volume":"149","author":"Atallah","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): Results of pivotal (phase II) trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: Results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_41","first-page":"2986","article-title":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia","volume":"110","author":"Zhang","year":"2025","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","article-title":"Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib and asciminib: A phase 1b randomized clinical trial","volume":"11","author":"Jabbour","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2021-153065","article-title":"Updated safety and efficacy results of phase 1 study of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML)","volume":"138","author":"Qian","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2022-170698","article-title":"Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation","volume":"140","author":"Jiang","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2023-187740","article-title":"Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia chronic-phase (CML-CP) in a registrational randomized phase 2 study","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00277-023-05110-y","article-title":"Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed\/refractory (R\/R) mixed-phenotype blast phase of chronic myeloid leukemia","volume":"102","author":"Zhang","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12217","DOI":"10.1182\/blood-2022-164569","article-title":"Outcomes of olverembatinib based regimen in patients with Philadelphia chromosome-positive advanced leukemias: A real-world, single-center experience","volume":"140","author":"Wen","year":"2022","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e35652","DOI":"10.1002\/cncr.35652","article-title":"Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy","volume":"131","author":"Yu","year":"2025","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e68180f9","DOI":"10.1097\/01.HS9.0000968484.68180.f9","article-title":"Frontline combination of olverembatinib and PDT-all-2016 pediatric inspired protocol in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"7","author":"Zhu","year":"2023","journal-title":"HemaSphere"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CAD.0000000000001455","article-title":"Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A case study","volume":"34","author":"Tan","year":"2023","journal-title":"Anticancer Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11683","DOI":"10.1182\/blood-2022-165879","article-title":"Olverembatinib plus low-intensive regimen in frontline therapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A case series from a single center","volume":"140","author":"Lou","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1182\/blood-2023-184565","article-title":"Efficacy and safety of olverembatinib-based therapies in patients with Ph\/BCR-ABL1-positive acute lymphoblastic leukemia","volume":"142","author":"Zhao","year":"2023","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/blood-2022-166482","article-title":"The first report of third-generation TKI olverembatinib in adult Ph\/BCR-ABL1-positive acute lymphoblastic leukemia with T315I mutation and relapsed disease","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1007\/s00277-024-06027-w","article-title":"Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"103","author":"Zhu","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/bjh.19804","article-title":"Efficacy and safety of olverembatinib in adult BCR-ABL1-positive ALL with T315I mutation or relapsed\/refractory disease","volume":"205","author":"Liu","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ajh.27289","article-title":"A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study","volume":"99","author":"Tang","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/s41375-025-02674-8","article-title":"Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-center, single-arm, phase 2 trial","volume":"39","author":"Gong","year":"2025","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ding, J., and Li, W. (2023). Case report: Olverembatinib monotherapy: The chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1320641"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"key":"ref_60","first-page":"801","article-title":"Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"104","author":"Kong","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Candoni, A., Chiusolo, P., Lazzarotto, D., Sartor, C., Dargenio, M., Chiaretti, S., Skert, C., Giglio, T., Trappolini, S., and Fracchiolla, N.S. (2024). Ponatinib as a prophylactic or pre-emptive strategy to prevent cytological relapse after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia transplanted in complete cytological remission. Cancers, 16.","DOI":"10.3390\/cancers16112108"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/ajh.70026","article-title":"Efficacy and safety of the third-generation tyrosine kinase inhibitor olverembatinib in combination with inotuzumab ozogamicin for the treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients with refractory\/relapsed disease or persistent minimal residual disease bridging to hematopoietic stem cell transplantation","volume":"100","author":"Zhang","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2025-1574","article-title":"Results of POLARIS-1, a global phase 3 study (part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)","volume":"146","author":"Chen","year":"2025","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1182\/blood-2025-5561","article-title":"Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy","volume":"146","author":"Zhang","year":"2025","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/atm-25-28","article-title":"Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and\/or asciminib","volume":"13","author":"Kubota","year":"2025","journal-title":"Ann. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107374","DOI":"10.1016\/j.leukres.2023.107374","article-title":"Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy","volume":"133","author":"Khadadah","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","article-title":"Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia","volume":"101","author":"Luna","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with atyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood-2024-207892","article-title":"Efficacy and toxicity of frontline ponatinib plus blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the GIMEMA ALL2820","volume":"144","author":"Chiaretti","year":"2024","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","article-title":"Venetoclax-ponatinib for T315I\/compound-mutated Ph+ acute lymphoblastic leukemia","volume":"12","author":"Wang","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_73","unstructured":"Zhang, J., Guo, H., Chen, Z., Chen, X., Zou, Y., Yang, W., Zhai, Y., and Zhu, X. (2026, January 11\u201314). Efficacy and safety of olverembatinib combined with lisaftoclax in pediatric patients with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A phase 1b study. Proceedings of the European Hematology Association 2026, Stockholm, Sweden. abstract PF389."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/s41375-025-02709-0","article-title":"Heat stress targets and degrades BCR::ZBL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"39","author":"Yang","year":"2025","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14737167.2017.1366858","article-title":"Cost-effectiveness of kinase inhibitors for hematologic malignancies: A systematic and critical review","volume":"17","author":"Marchetti","year":"2017","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:31:12Z","timestamp":1781861472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121990"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121990","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}